Get started
Author

Marc Fellmann

Observed names: Fellmann Marc, Fellmann, Marc, M Fellmann, M. Fellmann
Observed institution: Pfizer (Switzerland)
ORCID: 0000-0003-0064-698X
Observed ORCID: 0000-0003-0064-698X
OpenAlex ID: A5019850545
Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
2021 · David T. Rubin, Walter Reinisch, et al. · Therapeutic Advances in Gastroenterology · 37
Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration
2024 · Claudia Traidl‐Hoffmann, Jamie Afghani, et al. · Allergy · 33
PDF
Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis and comorbid allergies
2023 · Peter Schmid‐Grendelmeier, Melinda J. Gooderham, et al. · Allergy · 16
PDF
Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12
2024 · Alessandro Armuzzi, David T Rubin, et al. · Inflammatory Bowel Diseases · 4
PDF
The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program
2024 · Vipul Jairath, David T Rubin, et al. · Inflammatory Bowel Diseases · 4
Navigating the Evolving Landscape of Atopic Dermatitis: Challenges and Future Opportunities: the 4 th Davos Declaration
2024 · Claudia Traidl-Hoffmann, Jamie Afghani, et al. · 3
PDF
Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: an analysis of the phase II OASIS and phase III ELEVATE UC 52 and ELEVATE UC 12 clinical trials
2024 · Charlie W. Lees, Joana Torres, et al. · Therapeutic Advances in Gastroenterology · 3
P465 Health-related quality of life from the Inflammatory Bowel Disease Questionnaire in patients with ulcerative colitis treated with etrasimod in the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
2023 · A Armuzzi, D T Rubin, et al. · Journal of Crohn s and Colitis · 3
Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open
2022 · Luc Biedermann, Marla C Dubinsky, et al. · Inflammatory Bowel Diseases · 3
PDF
Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study
2022 · Stephan R. Vavricka, Thomas Greuter, et al. · Therapeutic Advances in Gastroenterology · 2
Tu1868 THE EFFECT OF TOFACITINIB ON EXTRAINTESTINAL MANIFESTATIONS AT BASELINE IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS IN THE OCTAVE PROGRAM
2020 · David T. Rubin, Walter Reinisch, et al. · Gastroenterology · 2
P080 Extraintestinal Manifestations at Baseline, and Effect of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis in the OCTAVE Program
2019 · Rubin David, Reinisch Walter, et al. · The American Journal of Gastroenterology · 2
P1183 Multivariable analysis of baseline variables associated with efficacy outcomes in the ELEVATE UC clinical programme
2025 · B G Feagan, M Kayal, et al. · Journal of Crohn s and Colitis · 1
PDF
P0828 The impact of etrasimod on neutrophils in the ELEVATE UC clinical programme
2025 · M Allez, B Verstockt, et al. · Journal of Crohn s and Colitis · 1
PDF
P540 Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: An analysis of the phase 2 OASIS and phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials
2024 · C Lees, J Torres, et al. · Journal of Crohn s and Colitis · 1
PDF
P607 Efficacy and safety of tofacitinib in Ulcerative Colitis patients with extraintestinal manifestations in OCTAVE Open
2022 · D T Rubin, S R Vavricka, et al. · Journal of Crohn s and Colitis · 1
P52 Multivariable analysis of baseline variables associated with efficacy outcomes in the ELEVATE UC clinical programme
2025 · Saqib Rana, Brian G Feagan, et al.
Su1850: THE IMPACT OF ETRASIMOD ON NEUTROPHILS IN THE ELEVATE UC CLINICAL PROGRAM
2025 · Matthieu Allez, Bram Verstockt, et al. · Gastroenterology
Health-related quality of life from the Inflammatory Bowel Disease Questionnaire among patients with ulcerative colitis stratified by prior and concomitant therapies: results from the etrasimod ELEVATE UC clinical programme
2024 · A. Armuzzi, D. T Rubin, et al. · Zeitschrift für Gastroenterologie
The effect of etrasimod on faecal calprotectin and high-sensitivity C-reactive protein: results from the ELEVATE UC clinical programme
2024 · V. Jairath, D. T. Rubin, et al. · Zeitschrift für Gastroenterologie
Su1793 THE EFFECT OF ETRASIMOD ON FECAL CALPROTECTIN AND HIGHSENSITIVITY C-REACTIVE PROTEIN: RESULTS FROM THE ELEVATE UC CLINICAL PROGRAM
2024 · Vipul Jairath, David T. Rubin, et al. · Gastroenterology
P788 The effect of etrasimod on faecal calprotectin and high-sensitivity C-reactive protein: Results from the ELEVATE UC clinical programme
2024 · V Jairath, D T Rubin, et al. · Journal of Crohn s and Colitis
PDF
S916 Health-Related Quality of Life From the Inflammatory Bowel Disease Questionnaire in Patients with Ulcerative Colitis Stratified by Prior & Concomitant Therapies: Results From the Etrasimod ELEVATE UC Clinical Program
2023 · Alessandro Armuzzi, David T. Rubin, et al. · The American Journal of Gastroenterology
Su1802 HEALTH-RELATED QUALITY OF LIFE FROM THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH ETRASIMOD IN THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
2023 · Alessandro Armuzzi, David T. Rubin, et al. · Gastroenterology
S1023 Assessment of Health-Related Quality of Life and Patient-Reported Outcomes With Tofacitinib Treatment Stratified by Age in Patients From the OCTAVE Ulcerative Colitis Clinical Program
2022 · Marla C. Dubinsky, Luc Biedermann, et al. · The American Journal of Gastroenterology
Works count: 31
Citation count: 116
H-index: 4
I10-index: 3
Year
Topic
Type